Hummingbird Bioscience and Synaffix Enter License Agreement

Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program Synaffix to provide Hummingbird Bioscience access to proprietary ADC technologies Synaffix to receive up to $150m in upfront and milestone payments plus royalties   Amsterdam...

Related Keywords

San Francisco , California , United States , Amsterdam , Noord Holland , Netherlands , Innovent Biologics , Synaffixbv Synaffix , Youtube , Twitter , Platform Technology , Hummingbird Bioscience , Synaffix Enter License Agreement , Next Generation Antibody Drug Conjugate , Hummingbird Bio , Rational Antibody Discovery , Chief Executive Officer , Piers Ingram , Mersana Therapeutics , Shanghai Miracogen , Kyowa Kirin , Biogeneration Ventures ,